Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Haematologica. 2019 Aug;104(8):1521-1531. doi: 10.3324/haematol.2018.208587.
Minimal residual disease has emerged as an important prognostic factor for relapse and survival in acute myeloid leukemia. Eradication of minimal residual disease may increase the number of patients with long-term survival; however, to date, strategies that specifically target minimal residual disease are limited. Consensus guidelines on minimal residual disease detection by immunophenotypic and molecular methods are an essential initial step for clinical trials evaluating minimal residual disease. Here, we review promising targets of minimal residual disease prior to allogeneic stem cell transplantation. Specifically, the focus of this review is on the rationale and clinical development of therapies targeting: oncogenic driver mutations, apoptosis, methylation, and leukemic immune targets. We review the progress made in the clinical development of therapies against each target and the challenges that lie ahead.
微小残留病已成为急性髓系白血病复发和生存的重要预后因素。消除微小残留病可能会增加长期生存患者的数量；然而，迄今为止，专门针对微小残留病的策略有限。免疫表型和分子方法检测微小残留病的共识指南是评估微小残留病临床试验的重要初始步骤。在这里，我们回顾了异基因干细胞移植前微小残留病的有前途的靶点。具体而言，本综述的重点是针对以下靶点的治疗策略的原理和临床开发：致癌驱动突变、细胞凋亡、甲基化和白血病免疫靶点。我们回顾了针对每个靶点的治疗方法的临床开发进展以及未来面临的挑战。
